Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. Issue 6 (June 2017)

• Record Type: Journal Article
• Authors: Liu, Ken; Zhang, Xiang; Xu, Weiqi; Chen, Jinbiao; Yu, Jun; Gamble, Jennifer R; McCaughan, Geoffrey W
• Is Part Of: Clinical and translational gastroenterology. Volume 8:Issue 6(2017)
• Publication Date: 2017-06
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology; Gastrointestinal Diseases; Liver Diseases; Intestines -- Diseases; Stomach -- Diseases; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; Electronic journals; 616.33
• DOI: 10.1038/ctg.2017.28
• Languages: English
• ISSNs: 2155-384X

Abstract

Abstract : N/A: Traditional treatments for intermediate or advanced stage hepatocellular carcinoma (HCC) such as transarterial chemoembolization (TACE) and anti‐angiogenesis therapies were developed to starve tumor blood supply. A new approach of normalizing structurally and functionally abnormal tumor vasculature is emerging. While TACE improves survival in selected patients, the resulting tumor hypoxia stimulates proliferation, angiogenesis, treatment resistance and metastasis, which limits its overall efficacy. Vessel normalization decreases hypoxia and improves anti‐tumor immune infiltrate and drug delivery. Several pre‐clinical agents aimed at normalizing tumor vasculature in HCC appear promising. Although anti‐angiogenic agents with vessel normalizing potential have been trialed in advanced HCC with modest results, to date their primary intention had been to starve the tumor. Judicious use of anti‐angiogenic therapies is required to achieve vessel normalization yet avoid excessive pruning of vessels. This balance, termed the normalization window, is yet uncharacterized in HCC. However, the optimal class, dose and schedule of vascular normalization agents, alone or in combination with other therapies needs to be explored further.